

Paratus Clinical Appoints Megan Morrison as CEO, Expands National and Therapeutic Footprint with New Melbourne Site

7th July 2025 – Paratus Clinical Research, a leading Australian provider of dedicated clinical trial services, proudly announces the appointment of Megan Morrison as its new Chief Executive Officer, marking a significant milestone as the company celebrates over a decade of growth, innovation, and impact in the clinical research space.

With 24 years of clinical research experience, Megan brings a depth of industry knowledge and leadership to Paratus, having worked across sponsor, CRO, and now site-side roles. Her appointment reflects Paratus Clinical's continued commitment to operational excellence, patient-centric research, and strategic expansion.

"I'm incredibly excited to be joining Paratus Clinical at such a pivotal time," said Megan Morrison. "Being site-side allows me to bring my passion for research delivery to the forefront and I look forward to working closely with our teams to further strengthen our presence and impact in the Australian research landscape."

Paratus Clinical has spent the last 10 years building a reputation for high-quality, efficient, and reliable clinical trial delivery. With the upcoming opening of its fifth site in Melbourne this month, Paratus now operates a network of five purpose-built, research-only clinics along Australia's eastern seaboard. The new Melbourne site will not only serve primary care studies but will also focus on expanding access to psychiatric research, a growing area of unmet need.

"We're proud of what Paratus Clinical has achieved over the last decade – running over 200 trials across a wide range of therapeutic areas, working hand-in-hand with CROs and sponsors to ensure fast, high-quality patient recruitment and data delivery," said Morrison. "The launch of the Melbourne site and expansion into Psychiatric research further strengthens our national capabilities and positions us for even greater growth."

Dave Gardiner, Chairman of the Paratus board added "Megan Morrison's leadership will help shape the next phase of Paratus' evolution, ensuring the company remains a trusted research partner to sponsors and a valued provider in the communities it serves, we are very pleased to have someone of Megan's experience and stature lead us forward".

As Paratus Clinical enters its second decade, the company remains committed to excellence in patient care, industry collaboration, and innovation in clinical trial delivery.

For more information about Paratus Clinical and its expanding network of sites, visit: www.paratusclinical.com